

CITATION REPORT

List of articles citing

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

DOI: 10.1016/s0140-6736(18)31791-4
Lancet, The, 2019, 393, 678-688.

Source: <https://exaly.com/paper-pdf/73780744/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
305	Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study. 2019 , 144, 409-417		5
304	Glioblastoma Treatment Modalities besides Surgery. 2019 , 10, 4793-4806		52
303	Biostatistics pitfalls: Lessons learned from analysis of medical data. 2019 , 87, 105875		2
302	Management of Glioblastoma, Present and Future. 2019 , 131, 328-338		23
301	Neues zur Diagnostik und Therapie von Gliomen. 2019 , 2, 283-298		1
300	Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection. 2019 , 145, 143-150		15
299	Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. 2019 , 20, 1444-1453		16
298	From the Champion to the Team: New Treatment Paradigms in Contemporary Neurosurgery. 2019 , 131, 141-148		6
297	Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. 2019 , 129, 90-100		32
296	Oncogenic BRAF Alterations and Their Role in Brain Tumors. 2019 , 11,		33
295	A Role for NF- κ B in Organ Specific Cancer and Cancer Stem Cells. 2019 , 11,		52
294	Dose diversification in newly diagnosed glioblastoma. 2019 , 21, 701-702		
293	Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma. 2019 , 16, 273		3
292	Improving survival in molecularly selected glioblastoma. <i>Lancet, The</i> , 2019 , 393, 615-617	40	20
291	Neuroimaging for Radiation Therapy of Brain Tumors. 2019 , 28, 63-71		4
290	Changes of O-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review. 2019 , 11,		16
289	Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGF β Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up. 2019 , 11,		12

288	Intraoperative radiotherapy for glioblastoma: an international pooled analysis. 2020 , 142, 162-167	7
287	The influence of patient sex on clinical approaches to malignant glioma. 2020 , 468, 41-47	12
286	Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. 2020 , 9, 3-11	14
285	Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. 2020 , 146, 787-792	13
284	Clinical neuro-oncology for the neurologist. 2020 , 10, 458-465	2
283	Neues zur Diagnostik und Therapie von Gliomen. 2020 , 2, 35-50	
282	New hints towards a precision medicine strategy for IDH wild-type glioblastoma. 2020 , 31, 1679-1692	14
281	Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. 2020 , 21,	7
280	[Biomarkers in cardio-oncology patients]. 2020 , 61, 1114-1119	0
279	Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis. 2021 , 44, 1943-1955	3
278	MP-Pt(IV): A MAOB-Sensitive Mitochondrial-Specific Prodrug for Treating Glioblastoma. 2020 , 19, 2445-2453	1
277	Current clinical management of elderly patients with glioma. 2020 , 20, 1037-1048	1
276	A novel methylation signature predicts radiotherapy sensitivity in glioma. 2020 , 10, 20406	2
275	Redox Regulator Is Associated With Tumor Immunity in Glioma. 2020 , 11, 580934	8
274	NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma. 2020 , 10, 593578	8
273	Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance. 2020 , 21,	10
272	Proteasome inhibition for the treatment of glioblastoma. 2020 , 29, 1133-1141	17
271	Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. 2020 , 10, 1045	9

270	Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade. 2020 , 10, 840	13
269	Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cells. 2020 , 37, 73	8
268	Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?. 2020 , 22, 1887-1888	1
267	Diagnose und Therapie der Gliome des Erwachsenen. 2020 , 23, 65-75	
266	Effects of miR-373 Inhibition on Glioblastoma Growth by Reducing Limk1. 2020 , 2020, 7671502	1
265	Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells. 2020 , 533, 1497-1504	2
264	A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogession in Patients with IDH-Wildtype Glioblastoma. 2020 , 12,	11
263	Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable. 2020 , 10,	1
262	MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. 2020 , 22, 1553-1554	0
261	Radioresistance in Glioblastoma and the Development of Radiosensitizers. 2020 , 12,	20
260	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. 2020 , 20, 785-795	13
259	Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. 2020 , 2, vdaa082	11
258	Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma. 2020 , 2020, 8844313	5
257	Glioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section. 2020 , 31, 289-297	
256	Glioblastoma treatment guidelines: Consensus by the Spanish Society of Neurosurgery Tumor Section. 2020 , 31, 289-298	4
255	Early Treatment Response Assessment Using F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy. 2021 , 62, 918-925	8
254	Protective effect of c-Myc/Rab7a signal pathway in glioblastoma cells under hypoxia. 2020 , 8, 283	2
253	Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas. 2020 ,	39

252	Genomics models in radiotherapy: From mechanistic to machine learning. 2020 , 47, e203-e217	10
251	A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma. 2020 , 15, 97	7
250	How did lomustine become standard of care in recurrent glioblastoma?. 2020 , 87, 102029	40
249	Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know. 2020 , 162, 1929-1939	8
248	Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma. 2020 , 18, 142	8
247	PARP inhibition suppresses the emergence of temozolomide resistance in a model system. 2020 , 148, 463-472	3
246	TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. 2020 , 22, 1030-1043	15
245	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. 2020 , 22, 1162-1172	22
244	Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. 2020 , 10, 66	3
243	Telomere maintenance in interplay with DNA repair in pathogenesis and treatment of colorectal cancer. 2020 , 35, 261-271	7
242	Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. 2020 , 47, 1458-1467	30
241	Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?. 2020 , 12,	7
240	Lomustin/Temozolomid plus Bestrahlung. 2020 , 23, 41-43	
239	Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy. 2020 , 581, 119283	14
238	Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. 2020 , 12,	30
237	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. 2020 , 22, 1073-1113 ¹⁷⁸	
236	Stochastic growth pattern of untreated human glioblastomas predicts the survival time for patients. 2020 , 10, 6642	1
235	LncRNA MIR4435-2HG potentiates the proliferation and invasion of glioblastoma cells via modulating miR-1224-5p/TGFBR2 axis. 2020 , 24, 6362-6372	13

234	Mechanisms and therapeutic implications of hypermutation in gliomas. 2020 , 580, 517-523	172
233	Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development. 2020 , 20, 355-363	6
232	Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial. 2020 , 15, 83	5
231	Impact of initial midline shift in glioblastoma on survival. 2021 , 44, 1401-1409	4
230	Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. 2021 , 147, 253-262	1
229	Narrative review of palliative hypofractionated radiotherapy for high grade glioma. 2021 , 10, 846-862	3
228	What is New in Neuro-oncology?. 2021 , 39, 163-179	3
227	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. 2021 , 18, 170-186	204
226	Update on the management of elderly patients with glioblastoma: a narrative review. 2021 , 10, 899-908	1
225	MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. 2021 , 148, 1695-1707	4
224	Oridonin interrupts cellular bioenergetics to suppress glioma cell growth by down-regulating PCK2. 2021 , 35, 2624	0
223	Glioblastoma Break-in; Try Something New. 2021 , 14,	1
222	Estimating Glioblastoma Biophysical Growth Parameters Using Deep Learning Regression. 2021 , 12658, 157-167	0
221	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. 2021 , 635-665	
220	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease. 2021 , 3, vdab028	4
219	Closed-loop trans-skull ultrasound hyperthermia leads to improved drug delivery from thermosensitive drugs and promotes changes in vascular transport dynamics in brain tumors. 2021 , 11, 7276-7293	7
218	Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?. 2021 , 3, vdab008	4
217	Targeting Glioblastoma: The Current State of Different Therapeutic Approaches. 2021 , 19, 1701-1715	5

216	Central Nervous System Molecular Imaging. 2021 , 1261-1285	
215	A Review of Newly Diagnosed Glioblastoma. 2020 , 10, 574012	12
214	Adult Diffuse Astrocytic and Oligodendroglial Tumors. 2021 , 89, 737-749	1
213	Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas. 2021 , 26,	4
212	A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. 2021 , 124, 1379-1387	19
211	Approaching glioblastoma during COVID-19 pandemic: current recommendations and considerations in Brazil. 2021 , 79, 167-172	0
210	Single-shot bevacizumab for cerebral radiation injury. 2021 , 21, 77	2
209	Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection. 2021 , 152, 339-346	3
208	Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status. 2021 , 14,	2
207	Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies. 2021 , 42, 804-813	3
206	Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries. 2021 , 147, 3381-3390	3
205	Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. 2021 , 22,	0
204	The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. 2021 , 9, 35	3
203	PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging. 2021 , 11, 646387	8
202	A potentially effective drug for patients with recurrent glioma: sermorelin. 2021 , 9, 406	1
201	Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma. 2021 , 11, 653614	2
200	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. 2021 , 23, 1885-1897	3
199	TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. 2021 , 26, 647-e1304	1

198	Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma. 2021 , 86, 202-210	4
197	Telomerase reverse transcriptase promoter mutation- and O-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?. 2021 , 147, 84-94	3
196	Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics. 2021 , 44, 751-775	2
195	DNA Damage Repair Genes and Noncoding RNA in High-Grade Gliomas and Its Clinical Relevance.	
194	The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance. 2021 , 32, 171-180	1
193	Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma. 2021 , 11, 664149	0
192	Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives. 2021 , 97, 218-230	3
191	Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. 2021 , 27, 3704-3713	3
190	Radiogenomics of Gliomas. 2021 , 59, 441-455	2
189	Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. 2021 , 10,	5
188	Precision Oncology. 2021 , 1, 97-112	
187	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. 2021 , 11, 679702	3
186	The relationship between PLOD1 expression level and glioma prognosis investigated using public databases. 2021 , 9, e11422	2
185	Virtual Trials: Causally-validated treatment effects efficiently learned from an observational cancer registry.	
184	DNA Repair Mechanisms and Therapeutic Targets in Glioma. 2021 , 23, 87	4
183	Artesunate combined with verteporfin inhibits uveal melanoma by regulation of the /yes-associated protein signaling pathway. 2021 , 22, 597	
182	Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?. 2021 , 153, 537-545	1
181	Advances in the management of glioblastoma. 2021 , 92, 1103-1111	4

180	Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma. 2021 , 11, 695316	3
179	Doxorubicin Delivered via ApoE-Directed Reduction-Sensitive Polymersomes Potently Inhibit Orthotopic Human Glioblastoma Xenografts in Nude Mice. 2021 , 16, 4105-4115	4
178	Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit. 2021 , 153, 393-402	
177	Therapie maligner Gliome [Update 2021]. 2021 , 4, 345-355	
176	Glioblastoma: Emerging Treatments and Novel Trial Designs. 2021 , 13,	5
175	58/w mit zunehmender psychomotorischer Verlangsamung und Zephalgien. 2021 , 27, 79-84	
174	G-protein-coupled receptors as therapeutic targets for glioblastoma. 2021 , 26, 2858-2870	3
173	Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?. 2021 , 23, 1614-1615	
172	Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. 2021 , 163, 103372	6
171	Mutational burden and immune recognition of gliomas. 2021 , 33, 626-634	0
170	Multifocal high-grade glioma radiotherapy safety and efficacy. 2021 , 16, 165	2
169	Changes of healthy brain tissue after salvage radiotherapy of glioblastoma.. 2021 , 3, vda139	
168	Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells. 2021 , 13,	0
167	Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. 2021 , 112, 4736-4747	3
166	Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma. 2021 , 10, CNS74	1
165	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. 2021 ,	4
164	Brain Neoplasm. 2021 , 521-625	
163	High-Content Analysis-Based Sensitivity Prediction and Novel Therapeutics Screening for c-Met-Addicted Glioblastoma. 2021 , 13,	2

162	Primary Central Nervous System Tumors. 2020 , 295-325	1
161	Skull-Stripping of Glioblastoma MRI Scans Using 3D Deep Learning. 2019 , 11992, 57-68	4
160	Genomic Biomarker Assessment in Gliomas: Impacts of Molecular Testing on Clinical Practice and Trial Design. 2020 , 13, 209-215	2
159	Novel pyrano 1,3 oxazine based ligand inhibits the epigenetic reader hBRD2 in glioblastoma. 2020 , 477, 2263-2279	3
158	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. 2019 , 4,	44
157	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2020 , 38, 1081	48
156	EGFR and mTOR as therapeutic targets in glioblastoma. 2019 , 10, 4721-4723	4
155	Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. 2021 , 4, 17-43	15
154	The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review. 2020 , 21, 564-578	10
153	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. 2020 , 13,	33
152	Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis. 2020 , 22, 859-869	8
151	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 2020 , 18, 1537-1570	83
150	Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review). 2021 , 22, 1408	4
149	New Approaches to Glioblastoma. 2021 ,	0
148	The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study. 2021 , 1	3
147	The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01. 2019 , 7, 63-73	3
146	Gliome. 2019 , 1-14	
145	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.	

144	Lomustine and temozolomide for newly diagnosed glioblastoma with methylated promoter: Lessons from the CeTeG/NOA-09 trial.. 2019 , 8, S589-S591	
143	Gliome. 2020 , 1-14	
142	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. 2022 , 36, 113-132	1
141	Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. 2021 , 12, 770390	6
140	Current Status of Adjuvant Therapy for Glioblastoma and Potential Novel Therapies. 2020 , 29, 188-197	
139	Neuroonkologie. 2020 , 257-271	
138	Chemotherapy for Brain Tumors. 2021 , 357-383	
137	Gliome des Erwachsenenalters. 2021 , 1-12	
136	Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma. 2021 , 3, vdaa171	1
135	Glucose oxidase and L-arginine functionalized black phosphorus nanosheets for multimodal targeted therapy of glioblastoma. 2022 , 430, 132898	3
134	Gliome. 2020 , 997-1010	
133	Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma: Review. 2020 , 151, 67-98	1
132	Towards Population-Based Histologic Stain Normalization of Glioblastoma. 2020 , 11992, 44-56	
131	Improved risk stratification in younger wild-type glioblastoma patients by combining a 4-miRNA signature with promoter methylation status. 2020 , 2, vdaa137	0
130	Stereotactic radiosurgery for glioblastoma considering tumor genetic profiles: an international multicenter study. 2021 , 1-9	1
129	Leveraging machine learning predictive biomarkers to augment the statistical power of clinical trials with baseline magnetic resonance imaging. 2021 , 3, fcab264	0
128	Neues zur Diagnostik und Therapie von Gliomen. 2020 , 10, 199-214	
127	Newly Diagnosed Glioblastoma: A Review on Clinical Management. 2019 , 33, 91-100	35

126	Tumor-treating fields (TTFields)-based cocktail therapy: a novel blueprint for glioblastoma treatment. 2021 , 11, 1069-1086	
125	Gliome. 2022 , 448-454	
124	Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. 2021 , 526, 41-52	3
123	Cannabidiol By Prolong Survival in Patients With Glioblastoma Multiforme.. 2021 , 1, 77-82	2
122	Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma. 2021 , 11, 22057	
121	Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study. 2021 , 155, 343-351	0
120	Repurposing the Damage Repair Protein Methyl Guanine Methyl Transferase as a Ligand Inducible Fusion Degron.. 2022 ,	0
119	Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.. 2021 , 156, 407	
118	Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma.. 2021 , 15, 791776	0
117	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.. 2022 , 23, 57	0
116	Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms.. 2022 , 14,	0
115	Would they do it again? Final treatment decisions in malignant brain tumour patients-a caregiver's perspective.. 2022 , 30, 3985	0
114	Synthetic vascular grafts as a new treatment option for space-occupying tumor bed cysts.. 2022 , 1	
113	Patient-individual phenotypes of glioblastoma stem cells are conserved in culture and associate with radioresistance, brain infiltration and patient prognosis.. 2022 ,	1
112	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.. 2021 , JCO21020360	
111	Sociocognitive Functioning and Psychosocial Burden in Patients with Brain Tumors.. 2022 , 14,	1
110	Inhibition of the DNA repair enzyme TDP1 by the resin acid derivatives as a new way to increase the efficiency of glioblastoma chemotherapy. 2022 ,	
109	Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard?. 2022 , 10, 12-21	0

108 Quality of Life and Brain Cancer. **2022**, 385-408

107 Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma.. **2022**, 10,

2

106 Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma.. **2022**, 22, 87

1

105 Defining the impact of adjuvant treatment on the prognosis of patients with inoperable glioblastoma undergoing biopsy only: does the survival benefit outweigh the treatment effort?. **2022**,

1

104 Sarcopenia Diagnosed Using Masseter Muscle Diameter as a Survival Correlate in Elderly Patients with Glioblastoma.. **2022**,

0

103 Longitudinal [F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model.. **2022**, 10,

0

102 Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.. **2022**, 1

1

101 Research progress of anti-glioma chemotherapeutic drugs (Review).. **2022**, 47,

1

100 MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.. **2022**, 14,

1

99 Relapsing High-Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options.. **2022**, 12,

0

98 Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.. **2022**,

1

97 Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. **2022**, 82, 491

2

96 Targeting NQO1/GPX4-mediated ferroptosis by plumbagin suppresses in vitro and in vivo glioma growth.. **2022**,

0

95 Structure-activity relations of Pd(II) and Pt(II) thiosemicarbazone complexes on different human glioblastoma cell lines.

94 Gene Alterations Define Specific Features of a Subset of Glioblastomas.. **2021**, 23,

1

93 Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. **2022**, 24, 358-383

1

92 Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. **2021**,

4

91 Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy-GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study.. **2021**, 16, 240

0

90	Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma. 2021 , 287, 120128	1
89	The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.. 2022 , 157, 177	2
88	First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis.. 2022 , 12,	0
87	Emerging therapies for glioblastoma: current state and future directions.. 2022 , 41, 142	7
86	Usefulness and Limits of Tractography for Surgery in the Precentral Gyrus-A Case Report.. 2022 , 12, 231-236	
85	Image_1.tif. 2020 ,	
84	Image_2.tif. 2020 ,	
83	Image_3.tif. 2020 ,	
82	Image_4.tif. 2020 ,	
81	Image_5.tif. 2020 ,	
80	Image_6.tif. 2020 ,	
79	Image_7.tif. 2020 ,	
78	Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells.. 2022 , 14,	2
77	Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma.. 2022 , 14,	
76	Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.. 2022 , 23,	
75	Glioblastom. 2022 , 43, 239-245	
74	The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review.. 2022 , 1	1
73	Lung toxicity of CCNU in the treatment of progressive gliomas.	0

72	Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas. 2022 , 14, 2454	0
71	Detection of Temozolomide-Induced Hypermutation and Response to PD-1 Checkpoint Inhibitor In Recurrent Glioblastoma.	0
70	Immunomodulatory Effects by Photodynamic Treatment of Glioblastoma Cells In Vitro. 2022 , 27, 3384	2
69	Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.	0
68	Targeting interleukin-13 receptor α (IL-13R α) for glioblastoma therapy with surface functionalized nanocarriers. 2022 , 29, 1620-1630	
67	Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis. 12,	
66	Standard clinical approaches and emerging modalities for glioblastoma imaging.	
65	Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.	
64	Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.	0
63	Hypofraktionierte Strahlentherapie in modernisierter Klassiker.	
62	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?.	1
61	Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches. 2022 , 39,	2
60	Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.	0
59	Temozolomide [Just a Radiosensitizer?]. 12,	1
58	Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q [IMPROVE CODEL: the NOA-18 trial. 2022 , 22,	0
57	Glioblastoma Treatment: State-of-the-Art and Future Perspectives. 2022 , 23, 7207	3
56	Mechanical Properties of the Extracellular Environment of Human Brain Cells Drive the Effectiveness of Drugs in Fighting Central Nervous System Cancers. 2022 , 12, 927	
55	Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell-based therapeutic approaches.	0

- 54 Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma. **2022**, 13, 3
- 53 Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials. **2022**, 171, 242-258
- 52 Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures. **2022**, 109, 108929 0
- 51 MicroRNA-575 acts as a novel oncogene via targeting multiple signaling pathways in glioblastoma. **2022**, 104813 0
- 50 Optimization of Deep Learning Based Brain Extraction in MRI for Low Resource Environments. **2022**, 151-167
- 49 Tumor-Treating Fields in Glioblastomas: Past, Present, and Future. **2022**, 14, 3669 2
- 48 Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma. **2022**, 14, 3705 2
- 47 CRISPR/Cas9-mediated epigenetic editing tool: An optimized strategy for targeting de novo DNA methylation with stable status via homology directed repair pathway. **2022**,
- 46 Microbeam Irradiation as a Simultaneously Integrated Boost in a Conventional Whole-Brain Radiotherapy Protocol. **2022**, 23, 8319 0
- 45 Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. **2022**, 11, 2588 2
- 44 First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma.
- 43 FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma. **2022**, 23, 8675 0
- 42 Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth. **2022**, 1868, 166513
- 41 How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology?. **2022**, 105, 91-102 0
- 40 Postoperative communicating hydrocephalus following glioblastoma resection: Incidence, timing and risk factors. 12, 0
- 39 A Biomimetic Nanomedicine Targets Orthotopic Glioblastoma by Combinatorial Co-Delivery of Temozolomide and a Methylguanine-DNA Methyltransferase Inhibitor. 2200095 0
- 38 A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. 0
- 37 Current and promising treatment strategies in glioma. **2022**, 0

36	Establishment and characteristics of GWH04, a new primary human glioblastoma cell line. 2022 , 61,	0
35	Polymer Nanocarriers for Targeted Local Delivery of Agents in Treating Brain Tumors.	0
34	Current therapeutic options for glioblastoma and future perspectives. 1-12	1
33	[⁶⁸ Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [¹⁷⁷ Lu]Lu-PSMA therapy in relapsing high-grade glioma. 12,	0
32	Adolescent and Young Adult Glioma: Systematic Review of Demographic, Disease and Treatment Influences on Survival.	1
31	Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA. 2022 , 14, 5179	2
30	Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center. 2022 , 11, 5855	0
29	Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma. 2022 , 12, 1426	0
28	Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. 2022 , 14, 5494	0
27	Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3).	0
26	Challenges in glioblastoma research: focus on the tumor microenvironment. 2022 ,	0
25	Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics prospective multicenter cohort study. 2022 , 15,	0
24	Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. 2022 , 7, 100605	0
23	Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.	0
22	Virtual Trials: Causally-validated treatment effects efficiently learned from an observational cancer registry. 2023 , 135, 102450	0
21	Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas radiation oncologist perspective.	0
20	¹⁸ F-FET PET radiomics-based survival prediction in glioblastoma patients receiving radio(chemo)therapy. 2022 , 17,	0
19	Advances in Lipid-Based Codelivery Systems for Cancer and Inflammatory Diseases. 2202400	0

- 18 Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma. 12, ○
- 17 Conventional and emerging treatments of astrocytomas and oligodendrogliomas. ○
- 16 Key Clinical Principles in the Management of Glioblastoma. ○
- 15 Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. 12, ○
- 14 Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics. ○
- 13 Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort. 13, ○
- 12 Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas. **2023**, 15, 880 ○
- 11 Transdural Skull Base Infiltration by Glioblastoma: Case Report and Review of the Literature. **2023**, 2023, 1-4 ○
- 10 Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. **2023**, 161, 147-153 ○
- 9 Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas. **2023**, 165, 693-699 ○
- 8 Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles?. **2023**, 24, 4883 ○
- 7 Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma. **2023**, 15, 1745 ○
- 6 The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma. **2023**, 15, 1134 ○
- 5 Overcoming the blood brain barrier in glioblastoma: Status and future perspective. **2023**, ○
- 4 Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro. **2023**, 15, 2347 ○
- 3 Chemotherapy. **2023**, 7-159 ○
- 2 Understanding the activity of antibodydrug conjugates in primary and secondary brain tumours. ○
- 1 The role of cytoreductive surgery in multifocal/multicentric glioblastomas. ○

